News & Perspective

Sep 09, 2008

Sep 09, 2008

HHS funds work on new anthrax antitoxin

(CIDRAP News) – Emergent BioSolutions Inc. recently announced that it won a federal contract worth $24.3 million to develop a monoclonal antibody treatment to block the effects of anthrax toxin.

Aug 12, 2008

Aug 12, 2008

HHS evaluates proposals for new anthrax vaccine

(CIDRAP News) – Two Maryland pharmaceutical companies recently announced that they have submitted proposals to produce and deliver at least 25 million doses of a next-generation anthrax vaccine to the nation's Strategic National Stockpile.

Jun 03, 2008

Jun 03, 2008

HHS announces preparedness grants for public health, hospitals

(CIDRAP News) – The US Department of Health and Human Services (HHS) today announced that it is allocating states and major metropolitan areas $1.1 billion to strengthen public health preparedness and help healthcare facilities respond to emergency events such as an influenza pandemic or terrorist attack.

May 07, 2008

May 07, 2008

VaxGen sells anthrax vaccine to rival firm

(CIDRAP News) – VaxGen Inc. announced this week the sale of its experimental anthrax vaccine—which the US government pulled the plug on in 2006—to Emergent BioSolutions, maker of the only US-licensed anthrax vaccine.

Apr 08, 2008

Apr 08, 2008

DoD funds development of anthrax vaccine patch

(CIDRAP News) – Iomai Corp., a biotechnology company that specializes in needle-free vaccines, announced today that it will receive a grant from the US Department of Defense (DoD) to fund preclinical development of a patch-based anthrax vaccine.

The 1-year grant to Iomai, based in Gaithersburg, Md., will be in the form of a $943,856 cost reimbursement from the US Army Medical Research and Material Command, according to a press release from Iomai.

Feb 29, 2008

Feb 29, 2008

Judge dismisses suit to limit DoD anthrax vaccinations

(CIDRAP News) – A federal district judge has dismissed a lawsuit aiming to stop the Pentagon's mandatory anthrax vaccination program for troops serving in some areas overseas, the Associated Press (AP) reported today.

Judge Rosemary M. Collyer in Washington, DC, said the Food and Drug Administration (FDA) acted appropriately when it determined the vaccine was safe and approved its use, according to the AP.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»